Generic placeholder image

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5230
ISSN (Online): 1875-614X

Research Article

Parvovirus B19 Seroprevalence in Women with Bad Obstetric History in Kirkuk

Author(s): Abdulghani Mohamed Alsamarai*, Hala Majeed Hassan, Mohamed Almoustafa Alsamarai and Zainab Khalil Aljumaili

Volume 20, Issue 4, 2021

Published on: 29 November, 2021

Page: [359 - 366] Pages: 8

DOI: 10.2174/1871523020666210727142351

Price: $65

Abstract

Background: In the Iraqi community, abnormal pregnancy forms a major social and psychological health problem. The underlying etiology of this health phenomenon was varied and included sets of infections and autoimmune diseases. Globally human parvovirus 19 infection is common and the infection attributes to bad obstetric outcomes. The global maternal parvovirus B19 remote infection rate was within a range of 13.2% to 97.9%, while the range of acute infection was between 0.5% to 97.9%. In Arab countries, the IgG seroprevalence was from 53.3% to 74%, while IgM seroprevalence range was 2.2% to 84%.

Objective: To evaluate the role of ParvovirusB19 as an etiology of bad obstetric outcome in women in Kirkuk, Iraq.

Materials and Methods: Descriptive Case Control Study. Women included in the study were recruited from Kirkuk General Hospital and their age ranged from 14 to 48 years. A total of 663 women were included in the study, of them 237 were not pregnant, while 215 were pregnant. Additionally, the study included 211 women with inevitable abortion. Control group (306 women) women with a history of normal pregnancy included (Pregnant= 149; non-pregnant= 157). Clinical and laboratory investigations were conducted on all patients and control groups to exclude other causes. Medical and obstetric data and demographic characteristics were gathered through interviews according to a previously designed questionnaire. ELISA kits were used to determine Parvovirus B19 IgM and IgG antibodies.

Results: The overall parvovirus seroprevalence was 93% and with no significant difference between women with normal (89.5%) and those with abnormal (93.1%) pregnancy outcomes. In addition, parvovirus IgM overall seroprevalence was at56.3%. Furthermore, current parvovirus infection was higher in women with BOH (52.6%) than that in women with normal pregnancy (49.7%) outcomes. Parvovirus IgM seroprevalence was 52.6% in women with BOH and 49.7% in women with normal pregnancy, however, the difference was not statistically significant. In contrast, the acute infection with parvovirus was significantly (X2=11.8, P=0.001) lower in women with normal pregnancy (49.7%) than in those with inevitable abortion (64.9%). While the IgG seroprevalence difference was not significant between the two groups, infection seroprevalence was more frequent in housewives, uneducated women, large families, non-smokers, in rural areas, non-animal exposure areas, women with repeated abortion, congenital anomalies and anaemia.

Conclusion: Parvovirus B19 infection may be with bad obstetric outcomes if occurred during pregnancy and OR confirmed a significant association of the infection with parvovirus with smoking, occupation, crowding index, education, animal exposure and the number of repeated abortion.

Keywords: Parvovirus B19, abortion, congenital anomalies, crowding index, education, housewife.

[1]
Alsamarai, A.G.M.; Aljumaily, Z.K. Seroepidemiology of toxoplasma, rubella, cytomegalovirus and herpes simplex virus -2 in women with bad obstetric history. part.i: Toxoplasma and rubella infections. Our Dermatol Online, 2013, 4(4), 522-535.
[http://dx.doi.org/10.7241/ourd.20134.135]
[2]
Alsamarai, A.G.M.; Aljumaily, Z.K. Seroepidemiology of toxoplasma, rubella, cytomegalovirus and herpes simplex virus -2 in women with bad obstetric history. part.ii: Cytomegalovirus and herpes simplex virus infections. Our Dermatol Online, 2013, 4(4), 536-544.
[http://dx.doi.org/10.7241/ourd.20134.136]
[3]
Abdulghani, M.A.; Hala, M.M.; Amina, H.A. Autoantibodies in women with bad obstetric history. J. Imm. Cell Microbiol., 2016, 1, 9-18.
[4]
Alsamarai, A.G.M.; Majed, H.M.; Alobaidi, A.H. Interleuk6 [il-6], interleukin-17 [il-17] and angiopoietin in women with bad obstetric history, kirkuk, iraq. Am Res J Haematol, 2016, 1, 1-11.
[5]
Qiu, J.; Söderlund-Venermo, M.; Young, N.S. Human Parvoviruses. Clin. Microbiol. Rev., 2017, 30(1), 43-113.
[http://dx.doi.org/10.1128/CMR.00040-16] [PMID: 27806994]
[6]
Alsamarai, M.A. Seroepidemiology of parvovirus b19 (pvb19] and human papillomavirus [hpv] 16 and 18 in women with abnormal pregnancy outcomes: A review. AAJMS, In press
[7]
Vaughan, J. Patrick; Morrow, Richard H. World Health Organization. Manual of epidemiology for district health management; Vaughan, J. P.; Morrow, R. H., Eds.; World Health Organization, 1989. Available from: https://apps.who.int/iris/handle/10665/37032
[8]
Abdulghani, M.A.; Hala, M.M.; Amina, H.A. Human papilloma virus in women with bad obstetric history, kirkuk, iraq. JOJ Immuno Virology., 2016, 1(4), 555566.
[http://dx.doi.org/10.19080/JOJIV.2016.01.555566]
[9]
Kishore, J.; Srivastava, M.; Choudhary, N. Standardization of B19 IgG ELISA to study the seroepidemiology of parvovirus B19 in North Indian voluntary blood donors. Asian J. Transfus. Sci., 2010, 4(2), 86-90.
[http://dx.doi.org/10.4103/0973-6247.67022] [PMID: 20859505]
[10]
Emiasegen, S.E.; Nimzing, L.; Adoga, M.P.; Ohagenyi, A.Y.; Lekan, R. Parvovirus B19 antibodies and correlates of infection in pregnant women attending an antenatal clinic in central Nigeria. Mem. Inst. Oswaldo Cruz, 2011, 106(2), 227-231.
[http://dx.doi.org/10.1590/S0074-02762011000200018] [PMID: 21537685]
[11]
Zaki, E.; Goda, G. Seroprevalence of human parvovirus b19 and torch group as virology marker in maternal serum for diagnosis of unexplained recurrent abortion. Arch. Pathol. Lab. Med., 2010, 134(9), 850-650.
[12]
Fatemeh, K.; Ebrahim, M.; Batool, M. Prevalence of human parvovirus B19 infection in successful and unsuccessful pregnancy in Zahedan, South east of Iran. J Med Sci., 2006, 6(3), 495-497.
[http://dx.doi.org/10.3923/jms.2006.495.497]
[13]
Abul-Razak, S.H.; Asmaa, H.H.; Abbase, A. Seroprevalence of anti- Parvovirus.B19 IgG and IgM antibodies among pregnant women in Diyala province. Int. J. Recent Sci. Res., 2013, 4(11), 1677-1681.
[14]
Adam, O.; Makkawi, T.; Reber, U.; Kirberg, H.; Eis-Hübinger, A.M. The seroprevalence of parvovirus B19 infection in pregnant women in Sudan. Epidemiol. Infect., 2015, 143(2), 242-248.
[http://dx.doi.org/10.1017/S0950268814000600] [PMID: 24650427]
[15]
Ella, M.; Yair, A.; Zahava, S.; Michal, T.; Zahave, G. Laboratory assessment and diagnosis of congenital viral infections: Rubella, CMV,VZV,HSV, Parvovirus B19 and HIV. Reprod. Toxicol., 2006, 21, 350-382.
[http://dx.doi.org/10.1016/j.reprotox.2006.02.001] [PMID: 16564672]
[16]
Saddon, R.N.; Hassan, J.H. The association of acute human Parvovirus B19 infection and spontaneous miscarriage in Basrah, Iraq. MJBU, 2011, 129(5), 18-2.
[17]
Mirambo, M.M.; Maliki, F.; Majigo, M.; Mushi, M.F.; Moremi, N.; Seni, J.; Matovelo, D.; Mshana, S.E. The magnitude and correlates of Parvovirus B19 infection among pregnant women attending antenatal clinics in Mwanza, Tanzania. BMC Pregnancy Childbirth, 2017, 17(1), 176.
[http://dx.doi.org/10.1186/s12884-017-1364-y] [PMID: 28592274]
[18]
Hussein, A.A. Detection of Human Parvovirus B19 antibodies in Pregnant Women with Spontaneous Abortion. Fac Med Baghdad, 2016, 58, 80-84.
[http://dx.doi.org/10.32007/med.1936/jfacmedbagdad.v58i1.16]
[19]
Majeed, K.R. The seroprevalence of Parvovirus B19 among pregnant women with spontaneous abortion in Thi-Qar province, Iraq. J. Glob. Pharma Technol., 2018, 10(03), 1038-1044.
[20]
Kishore, J.; Misra, R.; Paisal, A.; Pradeep, Y. Adverse reproductive outcome induced by Parvovirus B19 and TORCH infections in women with high-risk pregnancy. J. Infect. Dev. Ctries., 2011, 5(12), 868-873.
[http://dx.doi.org/10.3855/jidc.1533] [PMID: 22169786]
[21]
Abdulhassan, L.F.; Hathal, H.D.; Abdullah, T.H. Detection of parvovirus b19 in bad obstetric history by using real time PCR. Iraqi JMS, 2017, 15(4), 350-357.
[22]
Salimi, V.; Gouya, M.M.; Esteghamati, A.R.; Safaie, A.; Heshmat, R.; Saadatmand, Z. Human parvovirus B19 infection. Iran. J. Public Health, 2008, 37(4), 9-25.
[23]
Kaiser, L.; Sükösd, F.; Veszprémi, B.; Arany, A.; Vizer, M.; Szabó, I.; Kisfaludy, N.; Magyar, E.; Pajor, L. Parvovirus B19 infection in hydrops fetalis. Orv. Hetil., 2000, 141(30), 1661-1665.
[PMID: 10962903]
[24]
Chen, A.Y.; Guan, W.; Lou, S.; Liu, Z.; Kleiboeker, S.; Qiu, J. Role of erythropoietin receptor signaling in parvovirus B19 replication in human erythroid progenitor cells. J. Virol., 2010, 84(23), 12385-12396.
[http://dx.doi.org/10.1128/JVI.01229-10] [PMID: 20861249]
[25]
Gratacós, E.; Torres, P.J.; Vidal, J.; Antolín, E.; Costa, J.; Jiménez de Anta, M.T.; Cararach, V.; Alonso, P.L.; Fortuny, A. The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome. J. Infect. Dis., 1995, 171(5), 1360-1363.
[http://dx.doi.org/10.1093/infdis/171.5.1360] [PMID: 7751717]
[26]
Sohrabi, A; Samar, AR; Makvan, M; Maraghi, SH; Razi, T; Darban, D Seroepidemiological study of human Parvovirus B19,Toxoplasma gondii and Chlamydia trachomatis in pregnant women referring to obstetrics and gynecology ward of Ahwaz Imam Khomeini hospital. 2013, 32, 20-35.
[27]
Valeur-Jensen, A.K.; Pedersen, C.B.; Westergaard, T.; Jensen, I.P.; Lebech, M.; Andersen, P.K.; Aaby, P.; Pedersen, B.N.; Melbye, M. Risk factors for parvovirus B19 infection in pregnancy. JAMA, 1999, 281(12), 1099-1105.
[http://dx.doi.org/10.1001/jama.281.12.1099] [PMID: 10188660]
[28]
Mossong, J.; Hens, N.; Friederichs, V.; Davidkin, I.; Broman, M.; Litwinska, B.; Siennicka, J.; Trzcinska, A.; VAN Damme, P.; Beutels, P.; Vyse, A.; Shkedy, Z.; Aerts, M.; Massari, M.; Gabutti, G. Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection. Epidemiol. Infect., 2008, 136(8), 1059-1068.
[http://dx.doi.org/10.1017/S0950268807009661] [PMID: 17956642]
[29]
Giorgio, E.; De Oronzo, M.A.; Iozza, I.; Di Natale, A.; Cianci, S.; Garofalo, G.; Giacobbe, A.M.; Politi, S. Parvovirus B19 during pregnancy: A review. J. Prenat. Med., 2010, 4(4), 63-66.
[PMID: 22439064]
[30]
Yaegashi, N.; Niinuma, T.; Chisaka, H.; Watanabe, T.; Uehara, S.; Okamura, K.; Moffatt, S.; Sugamura, K.; Yajima, A. The incidence of, and factors leading to, parvovirus B19-related hydrops fetalis following maternal infection; report of 10 cases and meta-analysis. J. Infect., 1998, 37(1), 28-35.
[http://dx.doi.org/10.1016/S0163-4453(98)90346-2] [PMID: 9733374]
[31]
Ashaka, O.S.; Agbede, O.O.; Omoare, A.A.; Ernest, S.K. Human parvovirus B19-induced anaemia in pre-school children in Ilorin, Nigeria. Afr. J. Lab. Med., 2018, 7(1), 615.
[http://dx.doi.org/10.4102/ajlm.v7i1.615] [PMID: 29850435]
[32]
Gallinella, G. Parvovirus B19 achievements and challenges. ISRN Virology, 2013, 2013, 33. Article ID 898730
[http://dx.doi.org/10.5402/2013/898730]

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy